Headquarters: Boston, Massachusetts, United States
52 week low:4.51
52 week high:11.24
Next ER:May 9, 2023 After Market Closes
Top Stories (PRTK)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and?military use. The company's lead FDA approved commercial product, NUZYRA® (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment of adult patients with CABP and ABSSSI caused by susceptible pathogens.
Talk about Paratek Pharmaceuticals Inc below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.